Update on Johnson & Johnson’s “Maximum Fair Price” (“MFP”) Implementation Plan for IPAY 2026

As part of their continuous efforts to comply with the Inflation Reduction Act (IRA), Johnson & Johnson is preparing to implement the “Maximum Fair Price” (“MFP”) effectuation requirements, which will take effect on January 1, 2026. 

“MFP” effectuation is a government mandate under the IRA that must be applied to select medications under Medicare Part D. This requirement is mandatory and applies to manufacturers with selected drugs. Starting in 2026, Johnson & Johnson will provide the “MFP” on its selected products, XARELTO®, STELARA®, and USTEKINUMAB. Please click here to read the full notice.